Features

Features

Features
Blood and Lymphatic Cancer: Targets and Therapy

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.